Abstract
Gut microbiota alterations in Parkinson’s disease (PD) have been found in several studies and are suggested to contribute to the pathogenesis of PD. However, previous results could not be adequately adjusted for a potential confounding effect of PD medication and disease duration, as almost all PD participants were already using dopaminergic medication and were included several years after diagnosis. Here, the gut microbiome composition of treatment-naïve de novo PD subjects was assessed compared to healthy controls (HC) in two large independent case-control cohorts (n=136 and 56 PD, n=85 and 87 HC), using 16S-sequencing of fecal samples. Relevant variables such as technical batches, diet and constipation were assessed for their potential effects.
Overall gut microbiome composition differed between PD and HC in both cohorts, suggesting gut microbiome alterations are already present in de novo PD subjects at the time of diagnosis, without the possible confounding effect of dopaminergic medication. Although no differentially abundant taxon could be replicated in both cohorts, multiple short chain fatty acids (SCFA) producing taxa were decreased in PD in both cohorts. In particular, several taxa belonging to the family Lachnospiraceae were decreased in abundance. Fewer taxonomic differences were found compared to previous studies, indicating smaller effect sizes in de novo PD.
Trial registration DUPARC: NCT04180865
NMDAT: NCT02650843
Competing Interest Statement
JMB received an honorarium for writing an article for the magazine "Kinetic" by Britannia Pharmaceuticals and owns exchange traded funds that might include stocks in medically-related fields. KM grants from The Finnish Parkinson Foundation, Hospital District of Helsinki and Uusimaa and Maire Taponen Foundation. SvdZ none. THM none. RL none. TN none. PL none. EM none. EJ has received a grant from the Finnish Parkinson Foundation. EP has received consulting fees from Abbvie, Boston Scientific, and Nordic Infucare. Speaker's honoraria from Abbott, Abbvie, and Nordic InfuCare. He is PI in Finland: International Adroit-study (Abbott DBS Registry of Outcomes for Indications over Time) 2021: Organized by Abbott. VK received consulting fees from Orion Pharma and Nordic Infucare AB, participated in advisory boards for Abbvie and Nordic Infucare AB, and received speker's honoraria from Nordic Infucare AB, GE Healthcare and Abbvie. FS has received grants from The Academy of Finland, The Hospital District of Helsinki and Uusimaa, OLVI-Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, The Wilhelm and Else Stockmann Foundation, The Emil Aaltonen Foundation, The Yrjo Jahnsson Foundation, Renishaw, and honoraria from AbbVie, Orion, GE Healthcare, Merck, Teva, Bristol Myers Squibb, Sanofi, and Biogen. FS is founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board and has received consulting fees and stock options from Axial Biotherapeutics. TvL has received grant support from the MJFF, the UMCG, Menzis, Weston Brain Institute and the Dutch Brain Foundation. Consultancy fees were received from AbbVie, Britannia Pharm., Centrapharm and Neuroderm. Speaker fees were received from AbbVie, Britannia Pharm. and Eurocept. PABP, LP, PA, and FS have patents issued (FI127671B & US10139408B2) and pending (US16/186,663 & EP3149205) that are assigned to NeuroBiome Ltd.
Clinical Protocols
https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-020-01811-3
https://clinicaltrials.gov/ct2/show/NCT04180865
https://clinicaltrials.gov/ct2/show/study/NCT02650843
Funding Statement
DUPARC: Selfridges Group Foundation (Weston Brain institute). NMDAT: Turku University Hospital (VTR-funds), Paivikki and Sakari Sohlberg Foundation, Finnish Cultural Foundation (Varsinais-Suomi regional fund), Turku University Foundation, The Academy of Finland (295724, 310835), Hospital District of Helsinki and Uusimaa (UAK1014004, UAK1014005, TYH2018224), Finnish Medical Foundation, Finnish Parkinson Foundation, Maire Taponen Foundation. GAMDAT: The Finnish Foundation for Alcohol Studies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the University Medical Center Groningen gave ethical approval for the DUPARC study. The ethics committee of the Turku Hospital district gave ethical approval for the NMDAT and GAMDAT study. The ethics committee of the Hospital District of Helsinki and Uusimaa gave ethical approval for the Aho et al. follow-up study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sequencing data of the V4 region of the 16S rRNA gene will be made available via the European Nucleotide Archive upon publication. Sample metadata can be requested from the respective principal investigator of DUPARC, NMDAT, GAMDAT or the Aho et al. 2019 baseline and follow-up dataset via the corresponding author upon reasonable request, depending on associated privacy regulations.